Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.
Acetylgalactosamine
/ analogs & derivatives
Adult
Asialoglycoprotein Receptor
Female
Healthy Volunteers
Hepatitis B Surface Antigens
/ blood
Hepatitis B virus
/ genetics
Hepatitis B, Chronic
/ blood
Humans
Male
Middle Aged
Oligonucleotides
/ genetics
Oligonucleotides, Antisense
/ genetics
RNA, Viral
/ genetics
Sustained Virologic Response
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
15
04
2021
received:
23
12
2020
accepted:
17
05
2021
pubmed:
27
5
2021
medline:
11
1
2022
entrez:
26
5
2021
Statut:
ppublish
Résumé
RO7062931 is an N-acetylgalactosamine (GalNAc)-conjugated single-stranded locked nucleic acid oligonucleotide complementary to HBV RNA. GalNAc conjugation targets the liver through the asialoglycoprotein receptor (ASGPR). This two-part phase 1 study evaluated the safety, pharmacokinetics, and pharmacodynamics of RO7062931 in healthy volunteers and patients with chronic hepatitis B (CHB) who were virologically suppressed. Part 1 was a single ascending dose study in healthy volunteers randomized to receive a single RO7062931 dose (0.1-4.0 mg/kg), or placebo. Part 2 was a multiple ascending dose study in patients with CHB randomized to receive RO7062931 at 0.5, 1.5, or 3.0 mg/kg or placebo every month for a total of 2 doses (Part 2a) or RO7062931 at 3.0 mg/kg every 2 weeks, 3.0 mg/kg every week (QW), or 4.0 mg/kg QW or placebo for a total of 3-5 doses (Part 2b). Sixty healthy volunteers and 59 patients received RO7062931 or placebo. The majority of adverse events (AEs) reported were mild in intensity. Common AEs included self-limiting injection site reactions and influenza-like illness. Supradose-proportional increases in RO7062931 plasma exposure and urinary excretion occurred at doses ≥3.0 mg/kg. In patients with CHB, RO7062931 resulted in dose-dependent and time-dependent reduction in HBsAg versus placebo. The greatest HBsAg declines from baseline were achieved with the 3.0 mg/kg QW dose regimen (mean nadir ~0.5 log RO7062931 is safe and well tolerated at doses up to 4.0 mg/kg QW. Supradose-proportional exposure at doses of 3.0-4.0 mg/kg was indicative of partial saturation of the ASGPR-mediated liver uptake system. Dose-dependent declines in HBsAg demonstrated target engagement with RO7062931.
Sections du résumé
BACKGROUND AND AIMS
RO7062931 is an N-acetylgalactosamine (GalNAc)-conjugated single-stranded locked nucleic acid oligonucleotide complementary to HBV RNA. GalNAc conjugation targets the liver through the asialoglycoprotein receptor (ASGPR). This two-part phase 1 study evaluated the safety, pharmacokinetics, and pharmacodynamics of RO7062931 in healthy volunteers and patients with chronic hepatitis B (CHB) who were virologically suppressed.
APPROACH AND RESULTS
Part 1 was a single ascending dose study in healthy volunteers randomized to receive a single RO7062931 dose (0.1-4.0 mg/kg), or placebo. Part 2 was a multiple ascending dose study in patients with CHB randomized to receive RO7062931 at 0.5, 1.5, or 3.0 mg/kg or placebo every month for a total of 2 doses (Part 2a) or RO7062931 at 3.0 mg/kg every 2 weeks, 3.0 mg/kg every week (QW), or 4.0 mg/kg QW or placebo for a total of 3-5 doses (Part 2b). Sixty healthy volunteers and 59 patients received RO7062931 or placebo. The majority of adverse events (AEs) reported were mild in intensity. Common AEs included self-limiting injection site reactions and influenza-like illness. Supradose-proportional increases in RO7062931 plasma exposure and urinary excretion occurred at doses ≥3.0 mg/kg. In patients with CHB, RO7062931 resulted in dose-dependent and time-dependent reduction in HBsAg versus placebo. The greatest HBsAg declines from baseline were achieved with the 3.0 mg/kg QW dose regimen (mean nadir ~0.5 log
CONCLUSIONS
RO7062931 is safe and well tolerated at doses up to 4.0 mg/kg QW. Supradose-proportional exposure at doses of 3.0-4.0 mg/kg was indicative of partial saturation of the ASGPR-mediated liver uptake system. Dose-dependent declines in HBsAg demonstrated target engagement with RO7062931.
Identifiants
pubmed: 34037271
doi: 10.1002/hep.31920
pmc: PMC9291828
doi:
Substances chimiques
Asialoglycoprotein Receptor
0
Hepatitis B Surface Antigens
0
Oligonucleotides
0
Oligonucleotides, Antisense
0
RNA, Viral
0
RO7062931
0
locked nucleic acid
0
Acetylgalactosamine
KM15WK8O5T
Banques de données
ClinicalTrials.gov
['NCT03038113']
Types de publication
Adaptive Clinical Trial
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1795-1808Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 Roche Products Ltd. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Cell Death Dis. 2015 Mar 19;6:e1694
pubmed: 25789969
ACS Infect Dis. 2019 May 10;5(5):725-737
pubmed: 30403127
Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):381-91
pubmed: 19379126
ISRN Gastroenterol. 2013;2013:935295
pubmed: 23401786
Lancet. 2018 Nov 24;392(10161):2313-2324
pubmed: 30496122
J Infect Dis. 2020 Jul 23;222(4):611-618
pubmed: 32211776
Clin Mol Hepatol. 2017 Jun;23(2):125-127
pubmed: 28669139
J Hepatol. 2014 Dec;61(6):1407-17
pubmed: 25178562
Cold Spring Harb Perspect Med. 2015 Apr 01;5(4):
pubmed: 25833942
Mol Ther Nucleic Acids. 2017 Mar 17;6:116-132
pubmed: 28325278
Mol Ther Nucleic Acids. 2018 Jun 1;11:441-454
pubmed: 29858079
Sci Transl Med. 2017 Sep 27;9(409):
pubmed: 28954926
Clin Pharmacol Drug Dev. 2017 Jul;6(4):350-362
pubmed: 27739230
Clin Gastroenterol Hepatol. 2021 Mar;19(3):463-472
pubmed: 32473348
Front Immunol. 2020 May 12;11:849
pubmed: 32477347
Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):475-485
pubmed: 31144994
J Hepatol. 2016 Apr;64(4):781-9
pubmed: 26658683
Nat Rev Dis Primers. 2018 Jun 07;4:18035
pubmed: 29877316
Hepatology. 2020 Jul;72(1):19-31
pubmed: 31654573
Curr Treat Options Gastroenterol. 2019 Jun;17(2):271-291
pubmed: 31077059
Antivir Ther. 2019;24(2):105-115
pubmed: 30511941
J Hepatol. 2017 May;66(5):897-909
pubmed: 28043874
MAbs. 2017 Nov/Dec;9(8):1360-1369
pubmed: 28876162
Nucleic Acids Res. 2017 Dec 1;45(21):12388-12400
pubmed: 29069408
Antiviral Res. 2015 Sep;121:97-108
pubmed: 26129970
Cell Metab. 2018 Apr 3;27(4):714-739
pubmed: 29617640
J Hepatol. 2017 Oct;67(4):847-861
pubmed: 28778687
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875